Save Product
Product Details
Specificity
Specifically recognizes the target-SN38.
Source
Monoclonal Anti-SN38 Antibody, Mouse IgG1 is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.
Isotype
Mouse IgG1 | Mouse Kappa
Conjugate
Unconjugated
Reactivity
Chemical
Immunogen
SN38-OVA
Application
ApplicationRecommended UsageELISA0.1-8 ng/mLPurification
Protein A purified / Protein G purified
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) at 1 μg/mL, add Sacituzumab Govitecam in the 50% Mouse serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Immobilized Sacituzumab govitecam at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) with a linear range of 0.12-0.98 ng/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) with Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ fragment specific (min X Bov, Hrs, Ms Sr Prot) (Jackson, Cat. No. 109-035-098) used at 1:12000 concentration.
Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) is specific to Sacituzumab Govitecam and has no cross-reactivity with Trastuzumab Deruxtecan, Trastuzumab MMAE and Trastuzumab-DM1 (Routinely tested).
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing